Mov­ing on from a ma­jor set­back, Roche lines up a new Hunt­ing­ton's pro­gram for gene ther­a­py sub Spark

Un­daunt­ed by a se­vere set­back on Hunt­ing­ton’s dis­ease ear­li­er this year, Roche has head­ed straight back in­to the fray. On­ly this time, they’re adding to a slate of new tie-ups for their gene ther­a­py sub­sidiary Spark.

Spark an­nounced this morn­ing that they will col­lab­o­rate with US biotech NeuEx­cell to de­vel­op a gene ther­a­py for pa­tients suf­fer­ing from HD. As part of an agree­ment be­tween the two com­pa­nies, Spark will have ac­cess to NeuEx­cell’s gene ther­a­py plat­form, and NeuEx­cell’s re­search team will work with Spark to ad­vance the pro­gram.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER